A Helquat-like Compound as a Potent Inhibitor of Flaviviral and Coronaviral Polymerases.
Flaviruses
RNA-dependent RNA-polymerase
SARS-CoV-2
antiviral agents
helquat-like compound
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
15 Mar 2022
15 Mar 2022
Historique:
received:
21
02
2022
revised:
08
03
2022
accepted:
09
03
2022
entrez:
26
3
2022
pubmed:
27
3
2022
medline:
31
3
2022
Statut:
epublish
Résumé
Positive-sense single-stranded RNA (+RNA) viruses have proven to be important pathogens that are able to threaten and deeply damage modern societies, as illustrated by the ongoing COVID-19 pandemic. Therefore, compounds active against most or many +RNA viruses are urgently needed. Here, we present PR673, a helquat-like compound that is able to inhibit the replication of SARS-CoV-2 and tick-borne encephalitis virus in cell culture. Using in vitro polymerase assays, we demonstrate that PR673 inhibits RNA synthesis by viral RNA-dependent RNA polymerases (RdRps). Our results illustrate that the development of broad-spectrum non-nucleoside inhibitors of RdRps is feasible.
Identifiants
pubmed: 35335258
pii: molecules27061894
doi: 10.3390/molecules27061894
pmc: PMC8953834
pii:
doi:
Substances chimiques
RNA-Dependent RNA Polymerase
EC 2.7.7.48
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Czech Science Foundation
ID : 21-25280S
Références
Viruses. 2021 Aug 11;13(8):
pubmed: 34452451
Annu Rev Microbiol. 2004;58:183-205
pubmed: 15487935
Molecules. 2021 Jun 22;26(13):
pubmed: 34206406
SLAS Discov. 2021 Oct;26(9):1200-1211
pubmed: 34192965
Sci Adv. 2022 Jan 07;8(1):eabj4526
pubmed: 34995115
Biochem J. 2021 Jul 16;478(13):2405-2423
pubmed: 34198322
J Struct Biol. 2020 Aug 1;211(2):107548
pubmed: 32535228
Handb Exp Pharmacol. 2009;(189):53-84
pubmed: 19048197
Am J Public Health. 2016 Apr;106(4):606-12
pubmed: 26959260
SLAS Discov. 2020 Oct;25(9):1026-1037
pubmed: 32452709
Nat Rev Microbiol. 2016 Aug;14(8):523-34
pubmed: 27344959
PLoS One. 2015 Feb 26;10(2):e0117849
pubmed: 25719412
Biochem J. 2021 Jul 16;478(13):2465-2479
pubmed: 34198324
Nucleic Acids Res. 2021 Sep 27;49(17):10136-10149
pubmed: 34403466
Acta Virol. 1975 Nov;19(6):498
pubmed: 1999
Cell Res. 2022 Mar;32(3):322-324
pubmed: 35058606
Nucleic Acids Res. 2022 Jan 25;50(2):635-650
pubmed: 35018474
ACS Cent Sci. 2020 May 27;6(5):672-683
pubmed: 32483554
J Gen Virol. 2017 Jan;98(1):2-3
pubmed: 28218572
SLAS Discov. 2021 Jul;26(6):757-765
pubmed: 33874769
Rev Med Virol. 2020 Sep;30(5):e2118
pubmed: 32687681
Antimicrob Agents Chemother. 2015 Sep;59(9):5483-93
pubmed: 26124166
Antiviral Res. 2020 Oct;182:104899
pubmed: 32763313
Antiviral Res. 2018 Jun;154:66-86
pubmed: 29649496
J Biol Chem. 2020 Apr 10;295(15):4773-4779
pubmed: 32094225
N Engl J Med. 2020 Dec 31;383(27):2598-2600
pubmed: 33264539
Antiviral Res. 2019 Sep;169:104536
pubmed: 31202975
Nat Microbiol. 2020 Jun;5(6):796-812
pubmed: 32367055
Science. 2021 Dec 24;374(6575):1586-1593
pubmed: 34726479
Cell Death Differ. 2022 Feb;29(2):285-292
pubmed: 34862481
Nat Rev Microbiol. 2013 Dec;11(12):836-48
pubmed: 24217413
Nature. 2016 Mar 17;531(7594):381-5
pubmed: 26934220
Virus Res. 2017 Apr 15;234:1-3
pubmed: 28188807
Nat Commun. 2021 Aug 11;12(1):4848
pubmed: 34381037
ACS Infect Dis. 2021 Aug 13;7(8):2214-2220
pubmed: 34152728
Antiviral Res. 2016 Sep;133:119-29
pubmed: 27476046
SLAS Discov. 2021 Jun;26(5):620-627
pubmed: 33423577
Sci Rep. 2017 Dec 11;7(1):17309
pubmed: 29230036
J Biol Chem. 2020 May 15;295(20):6785-6797
pubmed: 32284326